SearchipHandbook Blog
Your source for expert commentary on IP management issues.
In ipHandbook Forums
|
Home > Author Index > SHORT, Jay M SHORT, Jay M
Dr. Short led the company’s highly successful initial public offering (IPO), which raised over $200 million in gross proceeds; at the time, it was the largest biotechnology IPO ever completed. His team also raised $300 million in committed funding from corporate partners, including Novartis, Syngenta, Dow, Merck, Dupont, Danisco, Givaudan, and Cargill. Dr. Short invented key genomic technologies for the discovery and optimization of products from microbial genes and gene pathways; these technologies are used in industrial, chemical, agricultural, and pharmaceutical applications. Under his leadership, Diversa was one of Deloitte and Touche’s “Technology Fast 50” for every year following the company’s IPO. Dr. Short also directed industry-leading efforts in bioethics through Diversa’s pioneering practice of establishing equitable benefit-sharing relationships with countries that provided genetic materials. Before joining Diversa, Dr. Short served as President of Stratacyte and V.P. of R&D and Operations at Stratagene. Dr. Short earned his B.A. in chemistry at Taylor University and his Ph.D. in biochemistry at CWRU. He is the author of more than 100 publications and is named as inventor on more than 100 issued patents. His patents were cited by MIT Magazine as among the top 10 in the world both in 2003 and 2004 across all industries. He received San Diego’s 2001 E&Y Entrepreneur of the Year Award and was the recipient of two first-place awards granted by the UCSD-Connect Program, which recognizes innovation in biotechnology. In 2003, he received the ABL Innovations in HealthCare Gold Award; in 2004, he received the Henry F. Whalen, Jr. Award for Business Development from the ACS. Dr. Short has served on the National Research Council (NRC) panel for the National Institute of Standards and Technology (NIST) and numerous other governmental committees. He currently serves as a Director for Invitrogen, Senomyx, and Anaptys. He is Entrepreneur-in-Residence for UCSD-Connect. In addition, he is an advisor for City National Bank, a fellow of the Explorer’s Club, and is founder and co-owner of Capia IP.
Contributions
|
|
About the ipHandbook | Policies and Disclaimers | Contact Us | Site Map
Developed with support from the Rockefeller Foundation. Distributed through Sponsorship.
©2007-2009. Concept Foundation, PIPRA, FIOCRUZ and bioDevelopments-Int.
Institute. Copyright and use. 
Printer Friendly
Jay M. Short is the Founder, President, and Chairman of the E.O. Wilson Biodiversity Foundation. He has more than 20 years’ experience working in biotechnology-based businesses, environmentally compatible development, and the commercialization of products derived from biodiversity. He is a Founder of Diversa and has also served as its CEO, President, and CTO. During his tenure, the company established the first agreement ever negotiated with a National Park to access biodiversity for commercial development. Under Dr. Short’s steward-ship, Diversa established similar pioneering agreements with Russia, Ghana, Kenya, Mexico, Bermuda, and Indonesia. These agreements were in alignment with and even exceeded the recommendations of the Convention on Biological Diversity. The company was also the first to generate biodiversity access royalties for Costa Rica.
Show All Abstracts
Abstract